Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
J Clin Immunol. 2022 Jan;42(1):10-18. doi: 10.1007/s10875-021-01149-6. Epub 2021 Oct 25.
The present study aimed to compare serum total IgA levels between severe and mild COVID-19 patients' groups and the control group.
In this cross-sectional study, 216 definite severe COVID-19 patients (as the inpatient group), 183 subjects with positive specific COVID-19 IgG with mild or no symptoms as the (outpatient group), and 203 healthy subjects with negative specific serology, as the control group were investigated. The cases' laboratory data were collected, and thereafter, statistical tests, including independent samples t test, ANOVA test, and post hoc test, were performed using SPSS software version 22.
The mean ± SD of IgA in all the included subjects was 2.23 ± 0.78 (g/L). According to the obtained results, there were statistically significant changes in IgA among the three study groups (P value < 0.05). This difference was significant between both outpatient and inpatient groups (P value < 0.05). The mean ± SD of serum IgG in all the subjects was calculated as 15.83 ± 5.73 (g/L). A strong statistically significant change was also seen in IgG among all three groups (P value < 0.001). Of note, there was a significant negative correlation between IgG and IgA total titers of the outpatient group (P value = 0.011*r = - 0.188).
It was shown that the total serum IgA and IgG levels are significantly associated with the severity of COVID-19 infection. As well, we found that total serum IgA and IgG are associated with the severity of illness. Since a low level of IgA is asymptomatic and high frequent in Iran and other countries, we suggest the evaluation of serum IgA levels in high-risk people and strengthening immune system in subjects with a low level of IgA, in order to reduce the rate of death. In this regard, oral or nasal mucosal vaccines in combination with parenteral vaccination are recommended due to increasing immunity versus COVID-19 by further secretion of the IgA antibody and preventing virus transmission.
本研究旨在比较重症和轻症 COVID-19 患者组与对照组之间的血清总 IgA 水平。
在这项横断面研究中,调查了 216 例确诊的重症 COVID-19 患者(住院组)、183 例具有阳性特定 COVID-19 IgG 且症状轻微或无症状的患者(门诊组)和 203 例具有阴性特定血清学的健康受试者(对照组)。收集了病例的实验室数据,然后使用 SPSS 软件版本 22 进行了独立样本 t 检验、方差分析和事后检验等统计检验。
所有纳入受试者的 IgA 平均值为 2.23±0.78(g/L)。根据获得的结果,三组研究对象的 IgA 有统计学显著变化(P 值<0.05)。门诊组和住院组之间的差异具有统计学意义(P 值<0.05)。所有受试者的血清 IgG 平均值为 15.83±5.73(g/L)。三组中 IgG 也有显著的统计学变化(P 值<0.001)。值得注意的是,门诊组 IgG 与 IgA 总滴度之间存在显著负相关(P 值=0.011*r=-0.188)。
结果表明,血清总 IgA 和 IgG 水平与 COVID-19 感染的严重程度显著相关。此外,我们发现血清总 IgA 和 IgG 与疾病的严重程度有关。由于 IgA 水平低在伊朗和其他国家无症状且高发,因此我们建议对高危人群评估血清 IgA 水平,并在 IgA 水平低的人群中增强免疫系统,以降低死亡率。在这方面,建议口服或鼻黏膜疫苗与肌肉注射疫苗联合使用,以通过进一步分泌 IgA 抗体增强对 COVID-19 的免疫力,并防止病毒传播。